Latest News

COVID vaccines could lose their punch within a year, experts say


 

“Dire, but not surprising”

Panagis Galiatsatos, MD, MHS, a pulmonologist at John Hopkins University, Baltimore, whose research focuses on health care disparities, said the survey findings were “dire, but not surprising.”

Johns Hopkins was another of the centers surveyed, but Dr. Galiatsatos wasn’t personally involved with the survey.

COVID-19, Dr. Galiatsatos pointed out, has laid bare disparities, both in who gets the vaccine and who’s involved in trials to develop the vaccines.

“It’s morally concerning and an ethical reckoning,” he said in an interview.

Recognition of the borderless swath of destruction the virus is exacting is critical, he said.

The United States “has to realize this can’t be a U.S.-centric issue,” he said. “We’re going to be back to the beginning if we don’t make sure that every country is doing well. We haven’t seen that level of uniform approach.”

He noted that scientists have always known that viruses mutate, but now the race is on to find the parts of SARS-CoV-2 that don’t mutate as much.

“My suspicion is we’ll probably need boosters instead of a whole different vaccine,” Dr. Galiatsatos said.

Among the strategies sought by the People’s Vaccine Alliance is for all pharmaceutical companies working on COVID-19 vaccines to openly share technology and intellectual property through the World Health Organization COVID-19 Technology Access Pool, to speed production and rollout of vaccines to all countries.

In the survey, 74% said that open sharing of technology and intellectual property could boost global vaccine coverage; 23% said maybe and 3% said it wouldn’t help.

The survey was carried out between Feb. 17 and March 25, 2021. Respondents included epidemiologists, virologists, and infection disease specialists from the following countries: Algeria, Argentina, Australia, Belgium, Bolivia, Canada, Denmark, Ethiopia, France, Guatemala, India, Italy, Kenya, Lebanon, Norway, Philippines, Senegal, Somalia, South Africa, South Sudan, Spain, United Arab Emirates, Uganda, United Kingdom, United States, Vietnam, Zambia, and Zimbabwe.

Dr. Offit and Dr. Galiatsatos reported no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

First pill for COVID-19 could be ready by year’s end
MDedge Dermatology
How to talk to patients reluctant to get a COVID-19 vaccine
MDedge Dermatology
Update: U.S. regulators question AstraZeneca vaccine trial data
MDedge Dermatology
COVID-19’s impact on lupus inpatients examined in study
MDedge Dermatology
Less sleep, more burnout linked to higher COVID-19 risk, study shows
MDedge Dermatology
COVID-19 variants now detected in more animals, may find hosts in mice
MDedge Dermatology
Vitamin D may protect against COVID-19, especially in Black patients
MDedge Dermatology
In U.S., lockdowns added 2 pounds per month
MDedge Dermatology
COVID-19 ‘long-haul’ symptoms overlap with ME/CFS
MDedge Dermatology
National Psoriasis Foundation recommends some stop methotrexate for 2 weeks after J&J vaccine
MDedge Dermatology